文献速递心力衰竭与心肌病

SGLT2抑制剂治疗射血分数保留心衰的成本效果

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该经济评估采用马尔可夫模型模拟美国HFpEF患者终身健康结局与直接医疗成本,比较标准治疗联合SGLT2抑制剂与标准治疗。

要点

  • ICER对SGLT2抑制剂成本及其对心血管死亡效应最敏感。
  • 扩大SGLT2抑制剂可及性需与降低药物成本措施相结合。

核心结论

  • 在2022年药价下,美国HFpEF成人标准治疗加用SGLT2抑制剂相比标准治疗具有中等或低经济价值。

研究设计与样本

  • 经济评估采用状态转移马尔可夫模型,模拟月度健康结局与直接医疗成本,模拟队列特征与EMPEROR-Preserved和DELIVER试验参与者相似。
  • SGLT2抑制剂基础-case年成本为4506美元,未来成本和效益按每年3%贴现,从美国医疗保健部门视角分析。

临床怎么用

  • 临床决策中应结合药物成本评估SGLT2抑制剂在HFpEF患者中的经济价值。
  • 为HFpEF患者扩大SGLT2抑制剂可及性时,需同步推动降低药物成本。

局限性

  • 模型输入参数来源于试验、文献和公开数据集,可能存在不确定性。
  • 经济评价基于2022年美国药价和医疗保健部门视角,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adding a sodium-glucose cotransporter-2 inhibitor (SGLT2-I) to standard-of-care treatment in patients with heart failure with preserved ejection fraction (HFpEF) reduces the risk of a composite outcome of worsening heart failure or cardiovascular mortality, but the cost-effectiveness in US patients with HFpEF is uncertain. OBJECTIVE: To evaluate the lifetime cost-effectiveness of standard therapy plus an SGLT2-I compared with standard therapy in individuals with HFpEF. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation conducted from September 8, 2021, to December 12, 2022, a state-transition Markov model simulated monthly health outcomes and direct medical costs. Input parameters including hospitalization rates, mortality rates, costs, and utilities were extracted from HFpEF trials, published literature, and publicly available data sets. The base-case annual cost of SGLT2-I was $4506. A simulated cohort with similar characteristics as participants of the Empagliflozin in Heart Failure With a Preserved Ejection Fraction (EMPEROR-Preserved) and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction (DELIVER) trials was used. EXPOSURES: Standard of care plus SGLT2-I vs standard of care. MAIN OUTCOMES AND MEASURES: The model simulated hospitalizations, urgent care visits, and cardiovascular and noncardiovascular death. Future medical costs and benefits were discounted by 3% per year. Main outcomes were quality-adjusted life-years (QALYs), direct medical costs (2022 US dollars), and incremental cost-effectiveness ratio (ICER) of SGLT2-I therapy from a US health care sector perspective. The ICER of SGLT2-I therapy was evaluated according to the American College of Cardiology/American Heart Association value framework (high value: <$50 000; intermediate value: $50 000 to <$150 000; and low value: ≥$150 000). RESULTS: The simulated cohort had a mean (SD) age of 71.7 (9.5) years and 6828 of 12 251 participants (55.7%) were male. Standard of care plus SGLT2-I increased quality-adjusted survival by 0.19 QALYs at an increased cost of $26 300 compared with standard of care. The resulting ICER was $141 200 per QALY gained, with 59.1% of 1000 probabilistic iterations indicating intermediate value and 40.9% indicating low value. The ICER was most sensitive to SGLT2-I costs and effect of SGLT2-I therapy on cardiovascular death (eg, increasing to $373 400 per QALY gained if SGLT2-I therapy was assumed to have no effect on mortality). CONCLUSIONS AND RELEVANCE: Results of this economic evaluation suggest that at 2022 drug prices, adding an SGLT2-I to standard of care was of intermediate or low economic value compared with standard of care in US adults with HFpEF. Efforts to expand access to SGLT2-I for individuals with HFpEF should be coupled with efforts to lower the cost of SGLT2-I therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Cohen, Isaza, Hernandez, et al. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2023. PMID: 36870047. doi:10.1001/jamacardio.2023.0077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。